In these studies, we demonstrated therapeutic potential of CD362+ UC-MSCs ameliorating sepsis injury in a polymicrobial sepsis model when delivered 4 h after sepsis induction, but not at 0 h and 24 h, suggesting the importance of timing in the administration of MSC therapy. The gene discussed is SDC2; the disease is Sepsis.